Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Single-Dose Trial To Determine The Safety And Pharmacokinetics Of Minocin (Minocycline) For Injection In Subjects With Renal Insufficiency

NCT02808052 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) as lead sponsor.

NCT NCT02808052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Single-Dose Trial To Determine The Safety And Pharmacokinetics Of Minocin (Minocycline) For Injection In Subjects With Renal Insufficiency
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Phase
Phase 1
Overall status
Terminated
Start date
May 29, 2017
Completion date
June 4, 2018
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects, renal insufficiency, acute, renal insufficiency, chronic